ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clini ...

Company aims for technology advancement and platform expansion with Korea's first influenza vaccine using an adjuvant Interim ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

Phase-III trial of indigenous one-shot dengue vaccine by Panacea Biotec shows promising results in India, aiming for ...

Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 ...

Primary progressive aphasia (PPA) is a rare neurological syndrome that gradually impairs a person’s language. Baycrest Canada ...

Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed dengue vaccine, DengiAll, is likely to be completed by October across 20 ...

A recent study found that only 15% of cancer survivors discussed trials with their healthcare providers, with ...

Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD - - Broadens global development program for vereki ...

Rahway, New Jersey Wednesday, July 16, 2025, 17:30 Hrs [IST] ...

Verastem Oncology releases primary results from phase 2 RAMP 201 trial of Avutometinib in combo with defactinib: Boston Tuesday, July 15, 2025, 09:00 Hrs [IST] Verastem Oncology, ...